Universität zu Köln

2021

Smeltzer, M., Bunn, B., Choi, Y. S., Coate, L., Corona-Cruz, J., Drilon, A., Duma, N., Edelman, M., Fidler, M. J., Gadgeel, S., Goto, Y., Herbst, R., Hesdorffer, M., Higgins, K., Labdi, B., Leal, T., Liu, S., Mazotti, J., Novello, S., Patel, S., Popat, S., Ramirez, R., Reckamp, K., Reguart, N., Soo, R., Tan, A., Wolf, J., Yano, S., Stiles, B. and Baird, A. (2021). The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers. J. Thorac. Oncol., 16 (10). S. S879 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

2020

Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Planchard, D., Heist, R. S., Solomon, B., Sebastian, M., Santoro, A., Reguart, N., Stammberger, U., Manganelli, L., Wu, H., Mais, A. and Dooms, C. (2020). Phase Ib study of LXH254+LTT462 in patients with KRAS- or BRAF-mutant NSCLC. Ann. Oncol., 31. S. S881 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S., V, Smit, E. F., Souquet, P., Vansteenkiste, J., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., Balbin, A., Fairchild, L., Giovannini, M. and Heist, R. S. (2020). Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study. Pneumologie, 74. S. S134 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

2018

Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

2017

Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

2016

Reguart, N., Pare, L., Gimenez-Capitan, A., Teixido, C., Galvan, P., Viteri, S., Rodriguez, S., Peg, V., Aldeguer, E., Ovalle, E., Vinolas, N., Merkelbach-Bruse, S., Lopez-Rios, F., Rosell, R., Molina-Vila, M. A. and Prat, A. (2016). Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

2015

Wolf, J., Hochmair, M., Kattan, J. G., Ang, M. -K., Garon, E. B., Groen, H. J. M., Heist, R., Ohashi, K., Felip, E., Reguart, N., Garcia Campelo, R., Soo, R., Paz-Ares, L., de Marinis, F., Smit, E. F., Giovannini, M., Squires, M., Cui, X., Zhang, Y. and Tan, D. (2015). A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann. Oncol., 26. S. 146 - 147. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041